Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Liabilities (2016 - 2025)

Neurocrine Biosciences' Total Liabilities history spans 16 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Total Liabilities rose 22.09% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 22.09%, while the annual FY2025 figure was $1.4 billion, 22.09% up from the prior year.
  • Total Liabilities reached $1.4 billion in Q4 2025 per NBIX's latest filing, up from $1.3 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.4 billion in Q4 2025 to a low of $582.3 million in Q2 2022.
  • Average Total Liabilities over 5 years is $870.0 million, with a median of $777.9 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: dropped 14.01% in 2022, then skyrocketed 60.86% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $698.5 million in 2021, then fell by 5.38% to $660.9 million in 2022, then skyrocketed by 54.24% to $1.0 billion in 2023, then rose by 10.75% to $1.1 billion in 2024, then increased by 22.09% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Total Liabilities are $1.4 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.2 billion (Q2 2025).